Trends and burden of inflammatory bowel disease in children (aged 0-14 years) in Asia and Europe, 1990-2021: a global burden of disease 2021 analysis

1990-2021年亚洲和欧洲0-14岁儿童炎症性肠病趋势及疾病负担:2021年全球疾病负担分析

阅读:2

Abstract

BACKGROUND: Inflammatory bowel disease (IBD), including Crohn's disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U), is a chronic immune-mediated gastrointestinal disorder. We analyzed the burden and epidemiological trends of IBD in children aged 0-14 years across Asia and Europe from 1990 to 2021, using the Global Burden of Disease (GBD) 2021 study data. METHODS: We extracted IBD data from the GBD 2021 database, which offers comprehensive estimates for diseases and risk factors across 204 countries and territories. Our analysis focused on prevalence, incidence, mortality, and disability-adjusted life-years (DALYs), emphasizing modifiable risk factors. We applied advanced statistical methods, including estimated annual percentage change (EAPC) to quantify trends, decomposition analysis to assess contributing factors, and Bayesian age-period-cohort (BAPC) modeling to evaluate temporal and demographic effects. ARIMA modeling forecasted future trends. RESULTS: From 1990 to 2021, IBD incidence, prevalence, and DALYs increased significantly in Asia but declined in Europe. In East Asia, prevalence rose from 1,265.78 cases (95% UI: 921.46-1,672.24) in 1990 to 1,402.33 cases (95% UI: 1,043.79-1,825.73) in 2021, while high-income Asian regions saw a decrease. ARIMA forecasts predict a continued rise in Asia's incidence over the next decade, with DALYs expected to decline. In Europe, incidence is projected to stabilize, and DALYs are anticipated to decrease. CONCLUSION: The rising IBD burden in Asian children may be associated with rapid socioeconomic development, lifestyle westernization, and environmental influences, as suggested by prior epidemiologic and mechanistic studies. These findings underscore the need for targeted public health strategies to curb Asia's increasing incidence and optimize disease management in Europe.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。